Respiratory

Description

• Montelukast sodium is an orally active compound that binds with high affinity and selectivity to the CysLT type-1 (CysLT1) receptor. Montelukast inhibits physiologic actions of LTD4  at the CysLT1 receptor without any agonist activity. It therefore acts as a leukotriene receptor antagonist.
• Fexofenadine hydrochloride, the pharmacologically active metabolite of terfenadine, is a potent and selective antagonist of peripheral H1-receptors. Fexofenadine is a third-generation antihistamine.
• Montelukast and fexofenadine hydrochloride combination is used for relief from physical symptoms associated with allergic rhinitis (intermittent or persistent) and allergic rhinitis associated with asthma. It prevents the aggravation and reduces the severity of the symptoms associated with those conditions, providing relief from repeated sneezing, runny nose, itchy eyes and general body fatigue.
• Recent studies have demonstrated that Allergic rhinitis (AR) when treated concomitantly with an antileukotriene (Montelukast) and an antihistamine (Fexofenadine), shows significantly better symptom-relief compared with the modest improvement of rhinitis symptoms with each of the treatment alone.

Indications

For the relief and/or prevention of symptoms associated with:

• Intermittent allergic rhinitis and persistent allergic rhinitis.
• Allergic rhinitis associated with asthma.